Wall Street Analysts Believe CareDx (CDNA) Could Rally 28.02%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 28% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Nov 27, 2025

SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication of the third manuscript from Surveillance HeartCare Outcomes Registry (SHORE) in the Journal of Heart and Lung Transplantation (JHLT). The analysis, titled “Multimodal Molecular Testing Prov.

Business Wire • Nov 24, 2025

CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences: Stephens Investment Conference in Nashville, TN. Fireside chat on Wednesday, November 19, 2025, at 8am CT. Piper Sandler Hea.

Business Wire • Nov 10, 2025

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On November 4, 2025, as an inducement material to acceptance of employment with CareDx, 49 new employees were awarded restricted stock units (RSUs) f.

Business Wire • Nov 7, 2025

CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data presentations featuring CareDx technologies at American Society of Nephrology (ASN) Kidney Week 2025, underscoring the power of molecular biomarkers to advance transplant.

Business Wire • Nov 6, 2025

CareDx, Inc (CDNA) Q3 2025 Earnings Call Transcript

CareDx, Inc ( CDNA ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Tina Jacobsen John Hanna - President, CEO & Director Nathan Smith - Chief Financial Officer Keith Kennedy - Chief Operating Officer Conference Call Participants Margarate Boeye - William Blair & Company L.L.C., Research Division Vidyun Bais - BTIG, LLC, Research Division William Bonello - Craig-Hallum Capital Group LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Harrison Parsons - Stephens Inc., Research Division Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Operator Hello, and thank you for standing by.

Seeking Alpha • Nov 5, 2025

CareDx Announces Third Quarter 2025 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company — a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $100.1 million, an increase of 21% year-over-year Testing services revenue of.

Business Wire • Nov 4, 2025

CareDx (CDNA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for CareDx (CDNA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Nov 5, 2025

CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates

CareDx (CDNA) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.14 per share a year ago.

Zacks Investment Research • Nov 5, 2025

CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Jeffrey John Teuteberg, MD, as Chief Medical Officer, effective October 1, 2025. Dr. Teuteberg brings more than two decades of experience in clinical transplantation, inclu.

Business Wire • Oct 27, 2025